Copy
New Scale For Prostate MRI
View this email in your browser
New Scale For Prostate MRI

PI-RADS (version 2) is a new scale in the United States which assigns a number from 1 through 5 to a patient’s prostate MRI results (table below). This scale will enable men to understand their own prostate MRI report with greater clarity. Also, physicians who interpret MRI results will have standardized criteria for evaluating and describing multiparametric images.
 

PI-RADS version 2 (for prostate MRI)

PIRADS 1.

Clinically significant cancer highly unlikely to be present

PIRADS 2.

Clinically significant cancer unlikely to be present

PIRADS 3.

Clinically significant cancer equivocal to be present

PIRADS 4.

Clinically significant cancer likely to be present

PIRADS 5.

Clinically significant cancer highly likely to be present

*Note: “Clinically significant” prostate cancer requires additional action.

PI-RADS stands for Prostate Imaging Reporting and Data System. PI-RADSv2 for prostate MRI is a potential breakthrough for men who are screening for prostate cancer, men on Active Surveillance, or men dealing with PSA recurrence after local treatment. PI-RADS is the result of many years of hard work, trials, and research from leading experts and institutions in the US and abroad. Special credit should be given to the AdMeTech Foundation, the American College of Radiology, and the European Society of Urogenital Radiology.

"PI-RADSv2 is a major step forward in the global standardization of prostate MRI and may help accelerate implementation of high quality diagnostic examinations all over the world. This will have a tremendously positive effect on the quality of patient care," said Jelle Barentsz, MD, Professor of Radiology at Radboud University, the Netherlands and co-chair of the Joint Committee.

The following excerpt of the PI-RADS document is of particular interest to patients: “…post biopsy changes, including hemorrhage and inflammation, may adversely affect the interpretation of prostate MRI for staging in some instances. Although these changes may persist for many months, they tend to diminish over time and an interval of at least 6 weeks or longer between biopsy and MRI should be considered for staging. See Page 4, PI-RADS v2 for more information.



DVDs from the 2014 conference are now available with a minimum donation of $150. To order > donate here. 
Website
Donate
Facebook
Twitter
YouTube
Copyright © 2014 Prostate Cancer Research Institute, All rights reserved.


unsubscribe from this list    update subscription preferences